Top

BY Jill Russell, Ph.D.

Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in triple-negative breast cancer. Gloria Echeverria, Ph.D., instructor in Experimental Radiation Oncology, presents these findings today at the 2019 San Antonio Breast Cancer Symposium, which provide possible leads for improving breast cancer treatment.

Triple-negative breast cancer is extremely...

A triple-negative breast cancer cell in the process of dying under attack from a combination of drugs in a laboratory experiment. Image: National Cancer Institute

BY Clayton Boldt, Ph. D.

Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...

BY Clayton Boldt, Ph. D.

Results from two MD Anderson-led clinical trials indicate that targeted therapies led to significant improvements in progression-free survival...

BY Ron Gilmore

Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center have discovered that removing an unwanted element from a protein known to suppress the immune system may eventually help clinicians better observe which cancer patients will benefit by treatment with immune checkpoint blockades.

Heng-Huan Lee, Ph.D., a postdoctoral fellow and Ying-Nai Wang,...

Glycans attach to the PD-L1 protein on tumors, making it hard to detect. MD Anderson researchers have found that purging glycans makes PD-L1 easier to find and accurately assess. Image courtesy of Cancer Cell.

BY Scott Merville

A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags cancer...

BY Scott Merville

V. Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been recognized for his “services to women’s health” with his appointment...

BY Scott Merville

Improvements in breast cancer treatment over the past five decades have reduced the mortality rate of women with the disease by 40 percent...

BY Scott Merville

MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...

BY Devon Carter

DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat...

BY Clayton R. Boldt, Ph.D.

Receiving a cancer diagnosis is a life-changing event, and the path through treatment can be among the hardest things a person goes through...